Plasmacytoid dendritic cells (pDCs) are the professional type I interferon (IFN)-producing cells, and upon activation they traffi c to lymph organs, where they bridge innate and adaptive immunity. Using multianalyte profi ling (MAP), we have mapped the key chemokines and cytokines produced in response to pDC activation, taking into consideration the role of autocrine IFN, as well as paracrine effects on other innate cells (e.g., monocytes and conventional DCs). Interestingly, we identify four distinct cytokine/chemokine loops initiated by Toll-like receptor engagement. Finally, we applied this analytic approach to the study of pDC activity in chronic hepatitis C patients. Based on the activation state of pDCs in fresh blood, the lack of agonistic activity of infectious virions, the production of a broad array of cytokines/chemokines once stimulated, and the direct effects of pDCs on other PBMCs, we conclude that the pDCs from hepatitis C virus (HCV)-infected individuals are fully functional and are, indeed, a viable drug target. In sum, this study provides insight into the use of MAP technology for characterizing cytokine networks, and highlights how a rare cell type integrates the activation of other infl ammatory cells. Furthermore, this work will help evaluate the therapeutic application of pDC agonists in diseases such as chronic HCV infection.
.1084/jem. 20070814 Human plasmacytoid DCs (pDCs) are responsible for robust production of type I IFNs ( 1, 2 ) . They express Toll-like receptor (TLR)-7 and -9, which recognize single-stranded RNA and double-stranded DNA, respectively ( 3 -5 ) . Upon stimulation, pDCs migrate to the T cell area of lymphoid organs via the high endothelial venules (HEVs), where they produce signifi cant amounts of type I IFNs, suggesting a central role in pathogen recognition and the induction of innate immunity ( 6, 7 ) . Increasing evidence indicates that pDCs are also critical in bridging innate and adaptive immune responses in the context of systemic viral or bacterial infections ( 1, 8 ) . This is caused, in part, by the production of IFNs, as well as their ability to participate in the recruitment of NK and activated T cells ( 9 ) . More recently, it has been demonstrated that pDC-derived IFN supports conventional DCs (cDCs) in the priming of CD8 ϩ T cells ( 8, 10 ) . Although this adjuvant eff ect is now accepted, the precise cytokine and chemokine network that accounts for pDC ' s role in establishing an infl ammatory microenvironment has been poorly characterized.
Taking advantage of multianalyte profi ling (MAP) technology, we have performed an indepth analysis of the cytokines and chemokines secreted by activated pDCs ( 1 ) . Using both TLR-7 and -9 agonists, we confi rmed what has been previously described concerning their secretory activity, and we identified additional infl ammatory molecules directly expressed by pDCs. Specifi cally, we have used MAP for characterization of the interactions between activated pDCs and other innate cells within the immune system. Interestingly, we identifi ed four distinct cytokine loops by which pDCs contribute to the initiation of an infl ammatory response: (a) molecules secreted by the pDC itself and independent of IFN production; (b) molecules secreted by the pDC and inhibited by paracrine IFN; (c) molecules secreted by the pDC and amplifi ed by paracrine IFN; and (d) molecules not produced by pDCs, but triggered by paracrine IFN. Herein, we map each of the four mechanisms and show data with representative pDC-produced and -induced analytes.
Although pDC research has primarily focused on their ability to produce IFNs, and understandably so, as pDCs have been shown to produce 19 diff erent type I IFNs, with this activity accounting for ‫ف‬ 60% of the transcriptional activity ( 11 ) , some studies have reported that pDCs secrete substantial amounts of other infl ammatory molecules. Specifi cally, it has been shown that pDC stimulation results in the production of TNF ␣ and IL-6, as well as the ␤ chemokines CCL3 and CCL4 ( 9, 12 -14 ) . That said, many of these studies fail to demonstrate on a per cell basis that pDCs are the true source of the analyte in question. Furthermore, none of these studies used a systematic approach to defi ne the extended array of molecules simultaneously produced by pDCs, nor has there been much consideration of the cells that are indirectly activated as a result of pDC-derived IFNs. Given the importance of pDCs in coordinating an infl ammatory milieu, we believe our eff orts off er critical information for understanding the programming of an antiviral or antibacterial response.
The analytic approach developed in this study lends itself to the evaluation of perturbations in the cytokine/chemokine network in diff erent disease states. Several reports have indicated subversion of pDC function in hepatitis C virus (HCV) patients ( 15 -18 ) , and for this reason, we chose to defi ne the functional status of pDCs in chronically infected individuals using MAP. This matter is of great importance, as it concerns not only the pathogenesis of HCV infection, but also the utility of novel therapeutic strategies based on targeting circulating pDCs. As shown here, by all measures, we fi nd that pDCs from HCV-infected individuals are fully functional and are, indeed, a viable target for immunotherapy.
RESULTS
pDC activation results in the production of a broad array of proinfl ammatory molecules To validate our stimulation protocols and defi ne the experimental conditions used herein, we purifi ed pDCs based on BDCA-4 expression and stimulated them with TLR-7 or -9 agonists. As previously demonstrated, pDC activation resulted in high levels of IFN ␣ production, expression of characteristic maturation markers, a shift in chemokine receptor expression, and an increased survival ex vivo (Fig. S1 , available at http://www.jem.org/cgi/content/full/jem.20070814/DC1) ( 6, 10 ) . We chose live infl uenza as an agonist, as it triggers rapid induction of IFN translation and protein accumulation such that it can be measured at an early time point by cytometric assays (Fig. S1 A and not depicted) . Notably, pDCs respond to live infl uenza in a TLR-7 -dependant manner ( 3, 19, 20 ) . To further characterize the eff ects of TLR engagement and to defi ne the role of pDCs in bridging innate and adaptive immunity, we used MAP technology to test the kinetics of production for 93 analytes using supernatants from stimulated pDCs. Using this initial screen, we defi ned a set of 12 molecules for this study (those not signifi cantly produced by activated pDCs or by other cell types within the unfractionated PBMCs are listed in the Supplemental materials and methods). We chose a 20-h time point based on the observed kinetics of production for the diff erent analytes ( Fig. 1 A and not depicted). With this technology, we identifi ed pDCs as being able to secrete a broad array of proinfl ammatory cytokines and chemokines. As shown, several cytokines (TNF ␣ , IL-6, and IL-1Ra) and chemokines (CCL3, CCL4, IL-8, and CXCL10) are produced in response to infl uenza or CpG-2216 stimulation (Fig. 1 A) . Although potential diff erences between infl uenza and CpG may refl ect distinct pathogeninduced responses (Fig. S2) , our interest was the defi nition of how activated pDCs initiate an infl ammatory milieu.
For several of the key analytes, we tested whether pDCs are the true source by performing intracellular cytokine staining ( Fig. 1 B ) . Indeed, this is the case for TNF ␣ , CXCL10, and IL-8. Notably, pDCs do not produce CCL2, suggesting that the CCL2 found in some of the experiments (and possibly other analytes) is caused by a contaminating cell population. In fact, the eff ect of pDCs on other cell types is of great importance, and to assess which analytes are produced versus induced by activated pDCs, we performed MAP analysis on PBMCs and PBMCs depleted of pDCs (PBMCs-pDC). Because of the observation that infl uenza is stimulatory for other cell types within the PBMCs (unpublished data), we focused on CpG, as it is primarily acting on the pDCs. As expected, CpG-2216 triggered the production of IFN ␣ , which was absent when pDCs were depleted ( Fig. 1 C ) . Interestingly, the pattern of molecules produced does not follow the MAP of purifi ed pDCs. We observe low amounts of TNF-␣ , CCL3, pDC-derived IFN inhibits secretion of IL-8 IL-8, also called neutrophil-activating peptide-1 and CXCL8, is derived from several cell types in response to infl ammatory stimuli. It functions as a chemoattractant and a stimulator of and CCL4 ( Fig. 1 C ) , all of which were highly expressed by purifi ed pDCs ( Fig. 1 ) . Notably, there were much higher levels of CCL2, CXCL10, and IL-1Ra produced by stimulated PBMCs than that observed from purifi ed pDCs ( Fig. 1 A, C ), yet these three analytes are completely dependant on the presence of pDCs, as is evident from the absence of these molecules in the PBMCs-pDC condition. Although the dependence on pDCs is not too surprising, as we were stimulating the cells with a TLR-9 stimulus, these observations are important, as they suggest multiple mechanisms by which pDC activation infl uences chemokine and cytokine production. These results were also confi rmed using FACS-purifi ed pDCs ( n ϭ 2; unpublished data). In further dissecting the mechanisms by which pDCs initiate infl ammatory responses, we defi ned four stimulation loops driven by TLR ligation and/or type I IFN production. We report on four molecules to illustrate these pathways: TNF-␣ , IL-8, CXCL10, and CCL2.
TLR engagement results in the production of TNF ␣ independent of autocrine IFN ␣ TNF ␣ is a pleiotropic infl ammatory cytokine. It is produced by several cell types, but is predominantly secreted by macrophages in response to TLR-2 and -4 stimulation ( 21, 22 ) . Depending, in part, on the TNF receptor expressed, cells may respond to cytokine stimulation by undergoing cell activation, cell division, or cell death ( 23 ) . Although pDCs have been previously reported to produce TNF ␣ , and some studies have explored its role in inhibiting IFN ␣ , the infl uence of the IFN ␣ cytokine loops on TNF ␣ production has not been explored ( 24 -26 ) . Interestingly, pDCs exposed to infl uenza or CpG secrete robust levels of TNF ␣ , producing on average 9.5 ϫ 10 9 molecules of TNF ␣ per pDC, which is calculated based on the molecular weight of TNF ␣ and the number of cells used in the stimulation ( Fig. 1 ) . As shown, pDCs are directly producing TNF ␣ ( Fig. 1 B ) , and strikingly, they are one of the dominant sources of this cytokine when PBMCs are stimulated with infl uenza ( Fig. 2 A , top plots) . In contrast, when PBMCs are stimulated by LPS, the majority of responding cells are macrophage, and pDCs account for a negligible amount of the TNF ␣ produced ( Fig. 2 A , bottom plots) . This is an important control, as it excluded the possibility that pDCs produce TNF ␣ as a consequence of infl ammation. However, as LPS does not trigger a strong IFN ␣ response, it does not exclude the possibility that pDC-derived IFN ␣ stimulates production of TNF ␣ via an autocrine loop. To address this possibility, we stimulated purifi ed pDCs with infl uenza in the presence of blocking antibodies specifi c for the interferon ␣ / ␤ receptor 2 (IFNAR2). No modulation of TNF ␣ was observed ( Fig. 2 B ) ; moreover, pDCs stimulated with purifi ed recombinant IFN ␣ 2b did not stimulate TNF ␣ production ( Fig. 2 C ) . Together, these data indicate that engagement of TLR on pDCs results in the production of high levels of TNF ␣ , and that this activation pathway is independent of its ability to produce type I IFNs ( Fig. 2 D ) . We have also demonstrated that CCL3 follows this pattern of expression stimulation of pDCs ( As shown, pDC-derived IFN ␣ is essential, as blocking IFNAR engagement or pDC-depletion from the PBMCs completely abrogated the expression of CXCL10. It should also be noted that after a short stimulation with CpG or IFN ␣ , B cells do not secrete measurable levels of CXCL10 ( Fig. 4 B and not depicted); however, after 20 h, it was indeed possible to detect direct activation of TLR-9 on B cells, resulting in the induction of CXCL10, confi rming the results of Vollmer et al. ( Fig.  4 D and not depicted) ( 35 ) . These data illustrate the complex cytokine loops responsible for expression of CXCL10; moreover, it demonstrates that in some cell types, IFN ␣ stimulation is suffi cient for triggering CXCL10 (monocytes and cDCs), whereas in others (pDCs), IFNAR signaling serves as an amplifi er of TLR activation, thus permitting the cell to achieve high levels of CXCL10 expression ( Fig. 4 E ) . We have also demonstrated that CCL4 follows this pattern of expression after CpG stimulation of pDCs (Fig. S3 ).
CCL2 is not produced, but is robustly induced, by activated pDCs
Monocyte chemotactic protein-1, renamed CCL2, is a proinfl ammatory chemokine and plays a principal role in the recruitment of monocytes to sites of injury and infl ammation ( 36 ) . The current models suggest that CCL2 produced in the tissue may drain to the lymph node and facilitate traffi cking of monocytes from the blood via the HEVs ( 37 ). We now demonstrate that activated pDC may be an additional trigger for CCL2 production. That said, the pDCs do not themselves produce CCL2 ( Fig. 1 B ) ; instead, activated pDCs induce production of CCL2 in PBMCs ( Fig. 5 A ) . Based on experiments with recombinant IFN ␣ 2a , we demonstrate that pDCderived type I IFNs may serve as the stimulus for CCL2 production ( Fig. 5 B ) , with the main cellular source being monocytes ( Fig. 5 C and not depicted). These data illustrate a fourth mechanism by which pDCs may infl uence the infl ammatory microenvironment of lymphoid organs ( Fig. 5 D ) . We have also demonstrated that IL1RA follows this pattern of expression after CpG stimulation of pDCs ( Fig. 1 C and not depicted).
pDCs in chronically infected HCV patients initiate a normal infl ammatory network
We next applied our insight from the MAP of pDCs to the evaluation of HCV-infected patients. It is well recognized that subversion of pathways responsible for the stimulation of type I IFNs is a critical feature of HCV pathogenesis and, moreover, therapeutic IFN ␣ 2 (given in combination with ribavirin) remains the standard of care for chronically infected patients ( 38 ) . These observations led to attention being focused on the functional state of pDCs in patients who become chronically infected. There remains signifi cant controversy in the fi eld ( 15, 18, 39, 40 ) , and arguably, some of the confusion stems from not fully addressing the complex role of pDCs in the establishment of an infl ammatory milieu; instead, studies on this subject have simply relied on IFN ␣ production as a measure of pDC activity.
angiogenesis ( 27, 28 ) . As shown in Fig. 1 , TLR stimuli induce IL-8 production in pDCs; although this may be expected given the broad tissue distribution of IL-8 production, pDCs are a unique case, as they also produce high amounts of IFNs, which are known to inhibit IL-8 production at the transcriptional level ( 29, 30 ) . To test this cytokine loop, we again performed intracellular cytokine staining on activated pDCs in the presence or absence of anti-IFNAR2. Notably, the amount of IL-8 produced on a per cell basis was not signifi cantly diff erent when autocrine stimulation by type I IFNs was inhibited ( Fig. 3 A ) . This result was confi rmed by Luminex on supernatants of stimulated pDCs ( Fig. 3 B ) . In contrast, the production of IL-8 by other PBMCs, monocytes in particular, increased dramatically in the presence of anti-IFNAR2 ( Fig. 3 C ) . This could also be observed when we evaluated the levels of IL-8 in the supernatants of CpG-2216 -stimulated PBMCs ( Fig. 3 D ) . This was quite revealing, as in the absence of IFNAR blockade, IL-8 levels were undetectable; and it suggested that pDC-derived TNF ␣ triggers IL-8 production ( 31 ). We confi rmed this hypothesis by exposing PBMCs to recombinant TNF ␣ in the presence of increasing amounts of IFN ␣ ( Fig. 3 E ) . As shown, TNF ␣ has the ability to induce IL-8 production by whole PBMCs, but this eff ect is antagonized once IFN ␣ is present in the media. As schematized in Fig. 3 F , we demonstrate that in respect to IL-8 induction, the following two opposing responses emerge from activated pDCs: induction by TNF ␣ and its simultaneous inhibition by type I IFN.
CXCL10 is produced and induced by activated pDCs IFN ␥ -inducible protein 10, now referred to as CXCL10, was fi rst identifi ed as an IFN ␥ -induced gene product produced by monocytes, endothelial cells, and fi broblasts ( 32 ) . It has also been shown that type I IFNs and TNF ␣ induces its production ( 33 ) , and it was recently reported that pDCs are included among the cell types that can produce CXCL10 ( 34 ) . Although our data support this result, with activated pDCs producing ‫ف‬ 9 ϫ 10 8 molecules of CXCL10/cell ( Fig. 1, A and B ) , an additional source of pDC-induced CXCL10 exists ( Fig. 1 C ) . We fi rst evaluated the production of CXCL10 by pDCs, and using anti-IFNAR2, we demonstrate that autocrine type I IFN amplifi es CXCL10 mRNA expression in CpG-stimulated pDCs ( Fig. 4 A ) . Next, we considered the eff ect of IFN ␣ on other cell types. When rIFN ␣ 2a was added to PBMCs, we observed CXCL10 production by monocytes and cDCs ( Fig. 4 B ) . We also evaluated CXCL10 production in lymphocytes and NK cells, but did not observe signifi cant levels of CXCL10 production (unpublished data). Interestingly, pDCs were not stimulated to produce CXCL10 in response to IFN ␣ alone, suggesting that synergy between TLR and IFNAR stimulation is required, accounting for the high production of CXCL10 by this cell type. To confi rm that pDCderived IFNs mediate release of CXCL10 after CpG stimulation, we monitored CXCL10 mRNA and protein in whole PBMCs in the presence of blocking antibodies, thus preventing the paracrine eff ects of type I IFNs ( Fig. 4 C and not depicted) . for their expression of defi ned maturation markers: CD80, CD86, CD83, HLA-DR, and the chemokine receptors CCR7 and CXCR3. In all patients tested, we observed resting-state levels of maturation markers ( Fig. 6 A ) , off ering evidence that circulating pDCs in SVR and NR HCV patients are in an inactive state. As a control that patient pDCs were able to undergo maturation, we stimulated cells and assessed patient (unpublished data). In addition, we fi nd lower numbers of pDCs in SVRs, suggesting that the presence of HCV in the plasma of patients is not directly responsible for the decrease in pDC number. We next assessed the phenotype of freshly isolated circulating pDCs as a direct measure of their activation state. pDCs were identifi ed based on expression of BDCA-2 and -4 (Fig. S4 A) . Gated cells were then analyzed ( Fig. 6 D and not depicted) . This observation was confi rmed by exposing pDCs derived from healthy individuals to primary isolate HCV in the presence of antiserum (unpublished data). As a positive control in our experiments, we used infl uenza A/PR8 as a pDC agonist. Finally, we tested if exposure to JFH-1J6 might abrogate pDC ' s ability to respond to TLR stimuli. In coculture experiments, we fi nd no evidence that live HCV virions alter a pDC ' s ability to produce IFN ␣ secondary to CpG and live infl uenza stimulation (unpublished data). We also evaluated if high viral titer plasma from patients could stimulate purifi ed pDCs (Fig. S5 , available at http:// www.jem.org/cgi/content/full/jem.20070814/DC1). These plasma contain free viruses, as well as anti-E2 antibodies that can lead to formation of antibody -virus complexes ( 46 ) . These data indicate that pDCs do not secret IFN ␣ in the presence of high viral titer plasma, suggesting that indirect entry of the virus, going through Fc receptors, does not lead to pDC activation. Together, these data support the absence of infection and the presence of quiescent pDCs within chronically infected HCV patients.
We next applied MAP to defi ne the infl ammatory network triggered by the activation of purifi ed patient pDCs. Data were analyzed using a bioinformatics tool developed by pDC phenotype. As shown in the representative plots, the pDCs from all three cohorts underwent a rapid maturation looking at several surface molecules (Fig. S4 B, solid lines) .
The lack of pDC activation in patients with high viral titer would suggest that HCV was neither infecting nor stimulating pDCs. To directly test this supposition, we used the replication-competent chimeric HCV, J6-JFH ( 41 -43 ). First, we evaluated direct infection of the pDC using a J6-JFH strain engineered to express cytoplasmic luciferase ( 44 ) . Although the hepatocellular line Huh-7.5 was readily infected, pDCs did not show any luciferase activity. Importantly, in this experiment, IL-3 was added to the pDC cultures to ensure survival over the 72-h time course ( Fig. 6 B ) . In addition, we evaluated pDC ' s expression of the recently identifi ed HCV coreceptor claudin-1 ( 45 ) . Whereas the HCV-permissive cell line Huh-7.5 expresses high levels of claudin-1, expression on pDCs was undetectable. These data support our observation that pDCs are not infected, but it does not exclude the possibility that viral engagement of pDCs might result in pDC activation.
To address this question, we tested if J6-JFH exposure might induce pDCs to produce IFN ␣ . Strikingly, no IFN ␣ was produced in response to live, replication-competent HCV Figure 7 . Purifi ed pDCs produce normal levels of TLR-9 -induced cytokines and chemokines. pDCs (mean purity ‫ف‬ 90%) isolated from 10 healthy donors (H, blue bars), 7 NRs (red bars), and 9 SVRs (yellow bars) were stimulated with 5 g/ml CpG-2216 for 20 h. Supernatants were harvested and MAP was performed using the Luminex technology. Data were analyzed with the OmniViz program, and Mann-Whitney tests were performed to obtain P values (statistically signifi cant values, P Յ 0.05, are shown in red). For each analyte, the range (R ϭ min − max) and the median value (m) are indicated, expressed in nanograms/milliliter. Each stimulation was performed in duplicate, using 10 5 pDCs in 200 l of culture media. * indicates the measured analytes that were not statistically different from unstimulated cells (not depicted; Mann-Whitney tests, P Ն 0.05).
and we observed the expected patterns of expression for all cytokines/chemokines. We conclude that the pDCs in HCV patients are normal across several independent criteria. Indeed, they are functionally active in regard to their ability to produce a broad spectrum of proinfl ammatory molecules, thus permitting the initiation of an appropriate infl ammatory network. DISCUSSION pDCs coordinate the production of four distinct chemokine and cytokine loops Using MAP, we have characterized the network of chemokines and cytokines produced upon pDC activation. Interestingly, this technology lends itself to working with rare cell populations such as pDCs, as simultaneous measurements can be achieved using small amounts of cell supernatant. In addition, through the use of recombinant cytokines and blocking antibodies to cytokine receptors, it has been possible to provide a detailed analysis of what occurs when pDCs are activated by TLR-7 or -9 agonists. We fi nd that although pDCs represent a small percentage of the PBMCs, they trigger a remarkable cascade of chemokine and cytokine production. We defi ne four distinct cytokine loops that together help OmniViz, and patient data are represented as whisker-box plots, showing absolute amounts of the respective cytokine or chemokine ( Figs. 7 ) . To the right of each plot, the range (R) and median (M) value is reported. The Mann-Whitney test was used to determine statistical diff erences between each pair of patient cohorts: healthy (H) versus NR chronically infected patients (N); healthy (H) versus SVRs (S); and NRs (N) versus SVRs (S). Each P value is reported, and those values Յ 0.05 are shown in red. Overall, there is a striking similarity between the patient cohorts in respect to their pDC activity. For several analytes, however, we did observe statistically signifi cant diff erences. Interestingly, in each of these instances, the HCV patients were producing higher levels of the respective analyte on a per pDC basis. In the case of IFN ␣ , CXCL10, and IL-6 production, we detected statistically signifi cant diff erences in stimulated pDCs isolated from SVR than from healthy individuals. To determine if any of these diff erences were relevant to the pDCs ability to provoke an infl ammatory cascade and to take into account the observed diff erences in absolute pDC number (unpublished data), we next defi ned the MAP of unfractionated PBMCs stimulated with CpG-2216 ( Fig. 8 ) . Notably, there were no statistically signifi cant diff erences across the three cohorts, Figure 8 . The pDC-mediated infl ammatory network is intact in chronically infected HCV patients. Freshly isolated PBMCs from 8 healthy donors (H, blue bars), 7 NRs (red bars), and 9 SVRs (S, yellow bars) were stimulated with 5 g/ml CpG-2216 for 20 h. Supernatants were harvested, and MAP was performed using the Luminex technology. Data were analyzed with the OmniViz program, and Mann-Whitney tests were performed to obtain P values (statistically signifi cant values, P Յ 0.05, are shown in red). For each analyte, the range (R ϭ min − max) and the median value (m) are indicated, expressed in nanograms/milliliter. Each stimulation was performed in duplicate using 10 6 pDCs in 200 l of culture media. * indicates the measured analytes that were not statistically different from unstimulated cells (not depicted; Mann-Whitney tests, P Ն 0.05).
transcription (and possibly translation) exert their control and help defi ne on a molecular level the regulation of these four cytokine loops.
A viable drug target in chronically infected HCV patients
There are nearly 200 million HCV-infected individuals worldwide, posing a signifi cant public health risk ( 51 ) . Approximately 30% of people infected with HCV resolve infection, whereas 70% progress to chronic infection. Given the recent observations concerning the role of type I IFN in facilitating cDCs to prime CD8 ϩ T cells, it has been considered that HCV inhibits pDC function, thereby limiting endogenous IFN production. Indeed, there have been several studies that report evidence for impaired DC subsets in chronically infected patients ( 17, 52, 53 ) . As it is diffi cult to reconcile these data with the observation that individuals chronically infected with HCV are not immunocompromised and that, in fact, they have high levels of endogenous IFN ( 54 ), we performed an in-depth evaluation of the phenotypic measures and functional activity of patient pDCs compared with normal controls. It is important to note that prior studies have limited their analysis to the pDC ' s ability to produce IFN ␣ / ␤ . In this study, we have considered the pDC in the context of its infl ammatory network and demonstrate that there is neither a defect in circulating pDCs nor in the ability of pDCs to engage other PBMCs for the establishment of a chemokine and cytokine network.
In addition to immunologic measures of pDC function, we considered the direct eff ects of replication-competent virus on freshly isolated pDCs. We report no direct infection and fi nd no evidence for HCV virions resulting in pDC activation ( Fig. 6, B and D ) . Notably, these experiments were performed using a highly sensitive measure of infection, as the recombinant viruses were engineered to express renilla luciferase (Rluc). We also demonstrate that pDCs do not express the HCV receptor claudin-1. Finally, we demonstrate evidence that virus -antibody immune complexes present in HCV plasma do not result in pDC activation (Fig. S5) . Given the lack of an intrinsic defect in chronically infected HCV patient pDCs, and the ability of circulating cells to respond appropriately to TLR stimulation, it is exciting to consider the use of pDC agonists as an alternative therapeutic intervention.
The current standard of care for chronic HCV infection is a 1-yr course of pegylated IFN ␣ (PEG-IFN) and ribavirin ( 55 ) . The PEG-IFN is administered subcutaneously and results in a blood level of 10 -25 ng/ml of type I IFN ␣ / ␤ . Although this therapy results in ‫ف‬ 50% viral clearance, there are signifi cant adverse eff ects, including mental health problems (e.g., irritability, depression, and anxiety), leukopenia, thrombopenia, and changes in vision. New therapeutics are desperately needed and pDC agonists are an exciting option for two reasons ( 56 -58 ) . First, it facilitates delivery of the IFN stimulation to the lymph node microenvironment. This is achieved by harnessing the biology of activated pDCs, which upregulate CCR7 and traffi c to the site of T cell priming. In this establish the proinfl ammatory response initiated by pDC activation (Fig. S6 , available at http://www.jem.org/cgi/content/ full/jem.20070814/DC1). Specifi cally, we have characterized these cytokine loops in respect to the pDCs innate ability to produce type I interferons. In the fi rst, activated pDCs secrete factors such as TNF ␣ and CCL3 in a manner that is triggered by TLR engagement and independent of IFNAR stimulation ( Fig. 2 and Fig. S3 ). In the second, IL-8 is the only molecule we identifi ed that follows a second pattern of expression; it is secreted by pDCs in response to TLR engagement, but its production is inhibited by IFNAR signaling ( Fig. 3 ) . Interestingly, pDCs are refractory to the inhibitory eff ects of IFN, suggesting that TLR-7 -and -9 -induced IL-8 production follows a diff erent signaling pathway from TNF ␣ -mediated IL-8 stimulation ( Fig. 3, A and B, and not depicted) . The third class of molecules is secreted by pDCs in response to TLR engagement, with their expression being enhanced by autocrine IFN. In the case of CXCL10 and CCL4, pDCderived IFN may also induce other cell types to produce these chemokines in a manner that is apparently independent of direct TLR stimulation ( Fig. 4 and Fig. S3 ). In the fourth cytokine loop, illustrated by CCL2 and also true for IL1Ra, IL1 ␤ , and IL-12p70, the pDCs do not produce, but instead induce, the production of these molecules by other cell types ( Fig. 5 and not depicted) . These results suggest a coordinated set of events that support recruitment of defi ned cells and the production of infl ammatory analytes for the initiation of an aff erent immune response.
Although we have not directly evaluated the signaling pathways that mediate these four cytokine loops, and there exists the caveat of extrapolating from mouse experiments that primarily rely on embryonic fi broblasts derived from knockout animals, published data, indeed, supports such a demarcation of events upon pDC activation. We predict that the IFN-independent production of TNF ␣ and CCL3 is mediated by an IFN regulatory factor-5 -regulated gene induction program ( 47 ) . This is predicated on the observation that Irf5 Ϫ / Ϫ hematopoietic cells respond to CpG by producing type I IFNs, but fail to secrete TNF ␣ in addition to other proinfl ammatory cytokines. Inhibition of IL-8 has been carefully characterized, and studies of the human IL-8 promoter demonstrate that IFN ␣ / ␤ suppresses its NF-B site-mediated transcription ( 30 ) . As IL-8 mediates neutrophil migration, its inhibition might be an important hallmark of pDC-initiated infl ammation in the lymph organs. Concerning the third signaling loop, the small but signifi cant amount of IFNARindependent CXCL10 is likely a result of TLR-induced phosphorylation of IFN regulatory factor-3, which acts as a homodimer and induces the transcription of CXCL10 ( 48, 49 ) . The autocrine and paracrine amplifi cation could be explained by the activation of IFN-stimulated gene factor 3, which will act on the ISRE within the promoter of CXCL10 ( 33 ) . Finally, it is also the IFN-stimulated gene factor that could account for the induction of CCL2, IL1Ra, IL-1 ␤ , and IL12p70 in cells that are predisposed toward producing these molecules ( 11, 50 ) . Clearly, additional modulators of gene way, it off ers a second potential benefi t. By concentrating the IFN ␣ production to the lymphoid organs, it may be possible to achieve similar activity with lower systemic levels of IFN ␣ . Thus, the stimulation of the hypothalamic -pituitary -adrenal axis may be less signifi cant, helping to avoid some of the more severe side eff ects of therapy, such as mood disorders.
In sum, we provide an in-depth characterization of the fi rst integrated map of the pDC chemokine/cytokine network, and conclude that the pDCs generated from patients with chronic HCV infection are phenotypically and functionally normal. This work also establishes a solid foundation for pDC immunotherapy, where the pDC itself would serve as the drug target, in turn releasing IFN ␣ / ␤ into the lymph node microenvironment and facilitating the activation of adaptive immune responses. We expect that the analytic approach developed in this study will be of use in the evaluation of perturbations in the cytokine/chemokine network in diff erent disease states.
MATERIALS AND METHODS
Cell preparation and isolation. Buff y coat were obtained from the É tablissement Fran ç ais du Sang. PBMCs were separated from granulocytes, erythrocytes, and platelets using Ficoll-Paque PLUS (GE Healthcare). Plasmacytoid DCs were isolated from 500 ϫ 10 6 PBMCs using the anti -BDCA-4 magnetic beads (Miltenyi Biotec) following the manufacturer ' s protocol. Three populations were obtained: PBMCs, enriched pDCs (90 -95% purity), and PBMCs depleted of pDCs (PBMCs-pDCs, Ͻ 0.01% pDCs). In all experiments, freshly isolated cells were used. Mouse monoclonal antibodies specifi c for human IFNAR2 (PBL biomedical) were used at 5 g/ml and added simultaneously with the pDC agonist used. For intracellular cytokine staining experiments, cells were stimulated for 5 h with live infl uenza virus, and GolgiPlug (BD Biosciences) was added during the last 2 h. Supernatant analysis. After stimulation, supernatants were harvested and conserved at − 80 ° C for further analysis. Chemokines and cytokines were measured by Luminex (12 plex kits; Biosource) following the manufacturer ' s instructions. In brief, 50 l of supernatant or standard was incubated with antibody-linked beads for 2 h, washed twice with wash solution, and incubated for 1 h with biotinylated secondary antibodies. A fi nal incubation of 30 min with streptavidin-PE preceded the acquisition on the Luminex 100IS. At least 100 events were acquired for each analyte. Values above or below the standard curves were replaced by the lowest or the highest concentrations measured. Where applicable, two-tailed nonparametric comparisons (Mann-Whitney U test) were performed to calculate P values. Statistical analyses were performed with the OmniViz program. , and CCL2 (eBioscience) antibodies were directly conjugated to PE. IFN ␣ staining was performed in two steps. First, mouse anti-IFN ␣ (PBL Biomedical) was used, followed by staining with a secondary antibody conjugated to PE (goat antimouse IgGs; Biosource). For PE-conjugated antibodies, cells were surface labeled, fi xed, permeabilized, and stained for intracellular cytokine production. For IFN ␣ detection, cells were fi xed and permeabilized fi rst so that the secondary antibody would not have the possibility to cross-react with surfacebound antibodies. pDC phenotype analysis ( Fig. 6 A ) was performed by staining for pDC surface lineage markers (BDCA-2 FITC, BDCA-4 APC; Miltenyi Biotec) associated with the desired phenotype marker in FL-2 channel (isotype PE, CD80 PE, CD86 PE, CD83 PE, HLA-DR PE, CXCR3 PE, and CCR7 PE; all purchased from BD Biosciences). Cells were incubated for 20 h at 4 ° C and analyzed by FACS, as indicated in the fi gure legend. Intracellular staining of claudin-1 was performed on fresh PBMCs (note, the available antibody recognizes an intracellular domain of the protein). Mouse anti -claudin-1 (Zymed Laboratories) was incubated for 20 h, followed by a secondary antibody conjugated to PE. Staining was followed by antibodies specifi c for surface markers BDCA-2/-4, thus allowing us to determine claudin-1 expression in pDCs.
Quantitative analysis of mRNA in stimulated cells. Total RNA from 3-h-stimulated cells were extracted using Trizol (Invitrogen), and cDNA was synthesized from 1 -2 g RNA using oligo-dT (Roche) and Superscript reverse transcriptase (Invitrogen) according to the manufacturers ' instructions. Quantitative real-time PCR was performed using the TaqMan gene expression assays technology (Applied Biosystems) for CXCL10 (Hs00171042_m1), CCL2 (Hs00234142_m1), and CCL4 (Hs00237011_m1). GAPDH was used as a housekeeping gene to normalize mRNA expression. The ratio of gene of interest versus housekeeping gene was calculated according to the following formula: ratio ϭ 2 − dCt (dCT ϭ mean Ct gene − mean Ct housekeeping). The mRNA fold increase was calculated as the ratio between mRNA in stimulated cells and mRNA in unstimulated cells. The reactions were run on a PTC200 equipped with a Chromo4 detector (MJ Research). The analyses were performed with Opticon Monitor software version 2.03 (MJ Research). All the measures were performed in duplicate and validated when the diff erence in threshold cycle (Ct) between the 2 measures was Ͻ 0.3.
Patient cohort.
The study protocol RBM 03 -59 was approved by the Institut National de la Sant é et de la Recherche M é dicale clinical investigation department and received ethical approval from the ethical committee of Necker Hospital (Consultative Committee for Protection of Persons in Biomedical Research). 22 HCV patients had chronic infection as defi ned by anti-HCV antibodies and HCV RNA positivity for a period of time Ͼ 6 mo. They all had biopsy-proven chronic hepatitis related to a genotype 1 infection. 21/22 patients were treated by a combination of pegylated interferon and ribavirin for at least 3 mo (Table S1 ); 12 were SVRs and 10 were NRs. SVRs were defi ned as individuals absent of HCV RNA for Ͼ 6 mo after termination of therapy. NRs had viral persistence and liver injury. Samples were collected by leukapheresis for 17/22 patients, and from whole blood donations for 5/22 individuals.
Preparation of Rluc-J6-JFH and luciferase assay. J6-JFH and J6-JFHexpressing Rluc were generated as previously described ( 44 ) . Regarding the luciferase-expressing virus, the Rluc gene was inserted between the P7 and NS2 proteins of the J6-JFH chimeric virus, allowing for a cytoplasmic expression of the enzyme during viral replication. Viral stocks were prepared by harvesting the supernatants of Huh7.5 cells infected with J6-JFH or Rluc-J6-JFH and storing them at − 80 ° C.
Luciferase assay. Cells exposed to Rluc-J6-JFH were washed twice with PBS and lysed with Renilla lysis buff er (Promega). Lysates were harvested and frozen at − 80 ° C for further analysis. Frozen samples were thawed, and 10 l of samples were mixed with luciferase assay substrate (Promega). Luciferase activity was measured using a luminometer (Lumat LB 9507; Berthold Technologies).
Online supplemental material. Table S1 shows the characteristics of the HCV patients included in the study. Fig. S1 shows that pDCs mature and secrete IFN ␣ in response to TLR ligands. Fig. S2 shows the production of proinfl ammatory chemokines and cytokines by purifi ed pDCs. Fig. S3 shows the diff erential regulation of CCL3 and CCL4 production. Fig. S4 shows that pDCs isolated from chronic HCV patients undergo a normal maturation when stimulated in vitro. Fig. S5 shows that purifi ed healthy pDCs do not produce IFN ␣ when they are exposed to high viral titer HCV plasma. Fig. S6 is a schematic summarizing the four diff erent loops of regulation described in the study. The online version of this article is available at http://www.jem .org/cgi/content/full/jem.20070814/DC1.
